The seventh new treatment in five years from a partnership between the diabetes division of Indianapolis-based Eli Lilly and Co. (NYSE: LLY) and Boehringer Ingelheim Pharmaceuticals Inc. has received federal approval. The U.S. Food and Drug Administration has cleared Jentadueto XR tablets for treatment of adults with type 2 diabetes.
The companies say it is the first extended-release therapy to emerge from the alliance. "Adults with type 2 diabetes are often required to take more than one medication to manage their condition, including some that have to be taken multiple times a day," said Boehringer Ingelheim Chief Executive Officer Paul Fonteyne. He added the treatment "offers adults with type 2 diabetes the convenience of a combination pill taken once a day to help lower blood sugar levels."
Jentadueto is a combination of linagliptin, which works to increase hormones that stimulate the pancreas to produce more insulin and the liver to produce less glucose, and Metformin, which lowers the liver’s glucose production and absorption in the intestine.
Lilly and Boehringer Ingelheim launched the collaboration in January 2011. It focuses on diabetes treatments by leveraging the strengths of two of the world’s largest pharmaceutical companies.